Royal Bank of Canada
AXDX

Royal Bank of Canada’s Accelerate Diagnostics AXDX Stock Holding History

Royal Bank of Canada’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,776
Closed -$6K – 6797
2024
Q4 		$6K Sell
4,776
-246
-5% -$408 ﹤0.01% 6474
2024
Q3 		$9K Sell
5,022
-122
-2% -$181 ﹤0.01% 6354
2024
Q2 		$6K Sell
5,144
-1,191
-19% -$1.24K ﹤0.01% 6475
2024
Q1 		$6K Sell
6,335
-2,980
-32% -$4.71K ﹤0.01% 6371
2023
Q4 		$37K Buy
9,315
+1,013
+12% +$5.36K ﹤0.01% 6113
2023
Q3 		$48K Buy
8,302
+610
+8% +$4.1K ﹤0.01% 5798
2023
Q2 		$62K Sell
7,692
-8
-0.1% -$60 ﹤0.01% 5664
2023
Q1 		$54K Sell
7,700
-25
-0.3% -$150 ﹤0.01% 5575
2022
Q4 		$55K Sell
7,725
-17,329
-69% -$189K ﹤0.01% 5819
2022
Q3 		$381K Buy
25,054
+3,028
+14% +$50.1K ﹤0.01% 4250
2022
Q2 		$219K Sell
22,026
-491
-2% -$4.34K ﹤0.01% 4745
2022
Q1 		$324K Sell
22,517
-1,125
-5% -$32K ﹤0.01% 4652
2021
Q4 		$1.23M Buy
23,642
+1,753
+8% +$97.6K ﹤0.01% 3598
2021
Q3 		$1.27M Buy
21,889
+725
+3% +$47.3K ﹤0.01% 3478
2021
Q2 		$1.71M Buy
21,164
+1,737
+9% +$138K ﹤0.01% 3200
2021
Q1 		$1.62M Buy
19,427
+913
+5% +$92.6K ﹤0.01% 3179
2020
Q4 		$1.4M Sell
18,514
-5,271
-22% -$472K ﹤0.01% 3227
2020
Q3 		$2.54M Buy
23,785
+3,638
+18% +$505K ﹤0.01% 2488
2020
Q2 		$3.05M Buy
20,147
+12,020
+148% +$1.19M ﹤0.01% 2300
2020
Q1 		$677K Sell
8,127
-1,187
-13% -$167K ﹤0.01% 3345
2019
Q4 		$1.57M Buy
9,314
+1,558
+20% +$257K ﹤0.01% 3083
2019
Q3 		$1.44M Buy
7,756
+7,695
+12,615% +$1.49M ﹤0.01% 3028
2019
Q2 		$13K Sell
61
-1
-2% -$196 ﹤0.01% 5917
2019
Q1 		$13K Sell
62
-1
-2% -$187 ﹤0.01% 5849
2018
Q4 		$7K Sell
63
-298
-83% -$44.2K ﹤0.01% 6021
2018
Q3 		$83K Buy
361
+55
+18% +$12.2K ﹤0.01% 4957
2018
Q2 		$67K Sell
306
-10
-3% -$2.24K ﹤0.01% 5019
2018
Q1 		$72K Sell
316
-1
-0.3% -$263 ﹤0.01% 4866
2017
Q4 		$82K Sell
317
-214
-40% -$50.2K ﹤0.01% 4922
2017
Q3 		$118K Buy
531
+201
+61% +$49.4K ﹤0.01% 4889
2017
Q2 		$91K Sell
330
-73
-18% -$19.8K ﹤0.01% 4816
2017
Q1 		$97K Buy
403
+276
+217% +$63.1K ﹤0.01% 4778
2016
Q4 		$26K Sell
127
-221
-64% -$52.5K ﹤0.01% 5614
2016
Q3 		$95K Hold
348
– – ﹤0.01% 4839
2016
Q2 		$50K Sell
348
-1,401
-80% -$188K ﹤0.01% 5114
2016
Q1 		$251K Buy
1,749
+187
+12% +$26.4K ﹤0.01% 4207
2015
Q4 		$335K Buy
1,562
+1,293
+481% +$236K ﹤0.01% 4135
2015
Q3 		$43K Sell
269
-17
-6% -$3.68K ﹤0.01% 5206
2015
Q2 		$74K Sell
286
-23
-7% -$5.49K ﹤0.01% 4998
2015
Q1 		$69K Sell
309
-192
-38% -$40.1K ﹤0.01% 4811
2014
Q4 		$96K Buy
501
+9
+2% +$1.93K ﹤0.01% 4748
2014
Q3 		$106K Buy
+492
New +$95.7K ﹤0.01% 4583
2013
Q4 		– Sell
-51
Closed -$7K – 5916
2013
Q3 		$7K Buy
+51
New +$4.55K ﹤0.01% 5526

Other funds holding AXDX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada's AXDX Position: Q1 2025 in Review

Royal Bank of Canada sold out of Accelerate Diagnostics (AXDX) in Q1 2025, closing a stake of 4,776 shares — an estimated $6K sold.

Royal Bank of Canada first reported a position in AXDX in Q3 2013 and held it in 43 quarters. The position peaked at $3.05M in Q2 2020. 43 funds tracked by Wall St. Rank hold AXDX as of Q1 2025.

  • Royal Bank of Canada reported no remaining Accelerate Diagnostics position as of Q1 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 4,776 Accelerate Diagnostics shares in Q1 2025, an estimated $6K.
  • Royal Bank of Canada first reported a position in Accelerate Diagnostics in Q3 2013 and held it in 43 quarters.
  • Royal Bank of Canada's Accelerate Diagnostics position peaked at $3.05M in Q2 2020.
  • 43 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2025.

Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.